# A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC

Source: https://onco.cc/trials/nct04501523/  
OnCo record `nct04501523` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of tislelizumab and capecitabine in triple-negative breast cancer, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, now recruiting.

## Summary

A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After NAC in TNBC is a phase 2, randomised interventional study registered as NCT04501523 by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, with a registry enrolment figure of 460 participants, started 2020-08-03 and due to reach its primary completion in 2027-08. Interventions recorded: Tislelizumab; capecitabine. Conditions listed: Triple-negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Must have histologically or cytologically confirmed triple negative (ER-/PR-/HER2-) invasive breast cancer, clinical stage II-III at diagnosis (AJCC 6th edition) based on initial evaluation by physical examination and/or breast imaging prior to study registration". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Also known as: Apollo
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04501523
- Phase: 2
- Setting: A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy After Neoadjuvant Chemotherapy in Triple-negative Breast Cancer
- Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
- Enrolled: 460

## Sources

- ClinicalTrials.gov NCT04501523: https://clinicaltrials.gov/study/NCT04501523

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Tislelizumab](https://onco.cc/drugs/tislelizumab/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04501523.json